Covered recipient · General Payments record
LISA B LAYA
Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease
General Payments · PY2018–2024
$4,679.35
- Reported across 272 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $294.32 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $87.97 | 4 |
| La Jolla Pharmaceutical Company | $53.95 | 3 |
| Gilead Sciences, Inc. | $44.59 | 2 |
| Merck Sharp & Dohme Corporation | $35.57 | 2 |
| ViiV Healthcare Company | $31.86 | 2 |
| Insmed, Inc. | $25.47 | 1 |
| PFIZER INC. | $14.91 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.14 | 01/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104144972 | CMS |
| ABBVIE INC. | $21.30 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104144974 | CMS |
| ABBVIE INC. | $25.53 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104144976 | CMS |
| ABBVIE INC. | $21.00 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104144978 | CMS |
| Gilead Sciences, Inc. | $16.05 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133817995 | CMS |
| Gilead Sciences, Inc. | $28.54 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133817997 | CMS |
| Insmed, Inc. | $25.47 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089568947 | CMS |
| La Jolla Pharmaceutical Company | $16.19 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154249432 | CMS |
| La Jolla Pharmaceutical Company | $19.30 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154249434 | CMS |
| La Jolla Pharmaceutical Company | $18.46 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154249436 | CMS |
| Merck Sharp & Dohme LLC | $20.74 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141727710 | CMS |
| Merck Sharp & Dohme LLC | $14.83 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141727708 | CMS |
| PFIZER INC. | $14.91 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132123305 | CMS |
| ViiV Healthcare Company | $15.44 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112726612 | CMS |
| ViiV Healthcare Company | $16.42 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112749076 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.